Linked Life Data

20466822

Source:http://linkedlifedata.com/resource/pubmed/id/20466822

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20466822rdf:typepubmed:Citationlld:pubmed
pubmed-article:20466822lifeskim:mentionsumls-concept:C0042769lld:lifeskim
pubmed-article:20466822lifeskim:mentionsumls-concept:C1175175lld:lifeskim
pubmed-article:20466822lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:20466822lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:20466822lifeskim:mentionsumls-concept:C0013935lld:lifeskim
pubmed-article:20466822lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:20466822lifeskim:mentionsumls-concept:C0054871lld:lifeskim
pubmed-article:20466822lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:20466822lifeskim:mentionsumls-concept:C1533157lld:lifeskim
pubmed-article:20466822pubmed:issue2lld:pubmed
pubmed-article:20466822pubmed:dateCreated2010-7-15lld:pubmed
pubmed-article:20466822pubmed:abstractTextA tetrahydroquinoline oxocarbazate (PubChem CID 23631927) was tested as an inhibitor of human cathepsin L (EC 3.4.22.15) and as an entry blocker of severe acute respiratory syndrome (SARS) coronavirus and Ebola pseudotype virus. In the cathepsin L inhibition assay, the oxocarbazate caused a time-dependent 17-fold drop in IC(50) from 6.9 nM (no preincubation) to 0.4 nM (4-h preincubation). Slowly reversible inhibition was demonstrated in a dilution assay. A transient kinetic analysis using a single-step competitive inhibition model provided rate constants of k(on) = 153,000 M(-1)s(-1) and k(off) = 4.40 x 10(-5) s(-1) (K(i) = 0.29 nM). The compound also displayed cathepsin L/B selectivity of >700-fold and was nontoxic to human aortic endothelial cells at 100 muM. The oxocarbazate and a related thiocarbazate (PubChem CID 16725315) were tested in a SARS coronavirus (CoV) and Ebola virus-pseudotype infection assay with the oxocarbazate but not the thiocarbazate, demonstrating activity in blocking both SARS-CoV (IC(50) = 273 +/- 49 nM) and Ebola virus (IC(50) = 193 +/- 39 nM) entry into human embryonic kidney 293T cells. To trace the intracellular action of the inhibitors with intracellular cathepsin L, the activity-based probe biotin-Lys-C5 alkyl linker-Tyr-Leu-epoxide (DCG-04) was used to label the active site of cysteine proteases in 293T lysates. The reduction in active cathepsin L in inhibitor-treated cells correlated well with the observed potency of inhibitors observed in the virus pseudotype infection assay. Overall, the oxocarbazate CID 23631927 was a subnanomolar, slow-binding, reversible inhibitor of human cathepsin L that blocked SARS-CoV and Ebola pseudotype virus entry in human cells.lld:pubmed
pubmed-article:20466822pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:languageenglld:pubmed
pubmed-article:20466822pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:citationSubsetIMlld:pubmed
pubmed-article:20466822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20466822pubmed:statusMEDLINElld:pubmed
pubmed-article:20466822pubmed:monthAuglld:pubmed
pubmed-article:20466822pubmed:issn1521-0111lld:pubmed
pubmed-article:20466822pubmed:authorpubmed-author:MyersMichael...lld:pubmed
pubmed-article:20466822pubmed:authorpubmed-author:DiamondScott...lld:pubmed
pubmed-article:20466822pubmed:authorpubmed-author:BatesPaulPlld:pubmed
pubmed-article:20466822pubmed:authorpubmed-author:SmithAmos...lld:pubmed
pubmed-article:20466822pubmed:authorpubmed-author:GreenbaumDoro...lld:pubmed
pubmed-article:20466822pubmed:authorpubmed-author:JingHuiyanHlld:pubmed
pubmed-article:20466822pubmed:authorpubmed-author:ShahParag PPPlld:pubmed
pubmed-article:20466822pubmed:authorpubmed-author:HurynDonna...lld:pubmed
pubmed-article:20466822pubmed:authorpubmed-author:WangTianhuaTlld:pubmed
pubmed-article:20466822pubmed:authorpubmed-author:KaletskyRache...lld:pubmed
pubmed-article:20466822pubmed:authorpubmed-author:PurvisJeremy...lld:pubmed
pubmed-article:20466822pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20466822pubmed:volume78lld:pubmed
pubmed-article:20466822pubmed:ownerNLMlld:pubmed
pubmed-article:20466822pubmed:authorsCompleteYlld:pubmed
pubmed-article:20466822pubmed:pagination319-24lld:pubmed
pubmed-article:20466822pubmed:dateRevised2011-8-3lld:pubmed
pubmed-article:20466822pubmed:meshHeadingpubmed-meshheading:20466822...lld:pubmed
pubmed-article:20466822pubmed:meshHeadingpubmed-meshheading:20466822...lld:pubmed
pubmed-article:20466822pubmed:meshHeadingpubmed-meshheading:20466822...lld:pubmed
pubmed-article:20466822pubmed:meshHeadingpubmed-meshheading:20466822...lld:pubmed
pubmed-article:20466822pubmed:meshHeadingpubmed-meshheading:20466822...lld:pubmed
pubmed-article:20466822pubmed:meshHeadingpubmed-meshheading:20466822...lld:pubmed
pubmed-article:20466822pubmed:meshHeadingpubmed-meshheading:20466822...lld:pubmed
pubmed-article:20466822pubmed:meshHeadingpubmed-meshheading:20466822...lld:pubmed
pubmed-article:20466822pubmed:meshHeadingpubmed-meshheading:20466822...lld:pubmed
pubmed-article:20466822pubmed:meshHeadingpubmed-meshheading:20466822...lld:pubmed
pubmed-article:20466822pubmed:year2010lld:pubmed
pubmed-article:20466822pubmed:articleTitleA small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells.lld:pubmed
pubmed-article:20466822pubmed:affiliationDepartment of Chemical and Biomolecular Engineering, Penn Center for Molecular Discovery, Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6383, USA.lld:pubmed
pubmed-article:20466822pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20466822pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed